Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19092749 | MACHINE LEARNING ENABLED PREDICTION OF MOLECULAR STRUCTURES AND PROPERTIES | March 2025 | March 2026 | Allow | 11 | 2 | 0 | Yes | No |
| 19020482 | GENETIC VARIANT DETECTION BASED ON MERGED AND UNMERGED READS | January 2025 | October 2025 | Allow | 9 | 2 | 0 | No | No |
| 18617448 | METHODS FOR DETECTING NUCLEIC ACID VARIANTS | March 2024 | June 2025 | Allow | 15 | 2 | 0 | Yes | No |
| 18595176 | METHODS AND SYSTEMS FOR PREDICTING RESPONSE TO ANTI-TNF THERAPIES | March 2024 | January 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18269902 | METHOD FOR IDENTIFYING SPECIES OF EUKARYOTE ON BASIS OF WHOLE GENOME ANALYSIS, AND USE THEREOF | February 2024 | April 2025 | Allow | 22 | 1 | 1 | Yes | No |
| 18522167 | METHODS FOR DETECTING BIALLELIC LOSS OF FUNCTION IN NEXT-GENERATION SEQUENCING GENOMIC DATA | November 2023 | January 2026 | Abandon | 25 | 1 | 0 | No | No |
| 18492794 | RAPID, COMPREHENSIVE AND SENSITIVE METHOD FOR NEOANTIGEN SCREENING FROM RECURRENT CANCER MUTATIONS | October 2023 | March 2025 | Allow | 16 | 3 | 0 | No | No |
| 18362754 | METHODS FOR DETECTING NUCLEIC ACID VARIANTS | July 2023 | October 2025 | Allow | 26 | 1 | 0 | No | No |
| 18178471 | Systems and Methods for Identifying and Expressing Gene Clusters | March 2023 | August 2025 | Allow | 29 | 3 | 1 | Yes | No |
| 17632800 | SYSTEM AND METHOD FOR RISK ASSESSMENT OF PARKINSONS DISEASE | February 2022 | March 2026 | Allow | 49 | 1 | 0 | No | No |
| 17613000 | Methods for Objective Assessment of Memory, Early Detection of Risk for Alzheimer's Disease, Matching Individuals With Treatments, Monitoring Response to Treatment, and New Methods of Use for Drugs | November 2021 | November 2025 | Allow | 47 | 1 | 1 | No | No |
| 17453728 | SURGERY PLANNING SYSTEM WITH AUTOMATED DEFECT QUANTIFICATION | November 2021 | December 2025 | Allow | 49 | 1 | 0 | Yes | No |
| 17477471 | NON-REDUNDANT GENE SET CLUSTERING METHOD AND SYSTEM, AND ELECTRONIC DEVICE | September 2021 | October 2025 | Abandon | 49 | 1 | 0 | No | No |
| 17384423 | MACHINE-LEARNING MODEL FOR RECALIBRATING NUCLEOTIDE-BASE CALLS | July 2021 | February 2026 | Allow | 54 | 3 | 0 | Yes | No |
| 17377804 | METHOD AND SYSTEM FOR EVALUATING POTENTIAL DRUG COMPOSITIONS FOR TARGET DISEASE | July 2021 | March 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17226529 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | April 2021 | September 2025 | Allow | 54 | 2 | 0 | Yes | No |
| 17226580 | METHODS AND PROCESSES FOR NON-INVASIVE ESTIMATION OF FETAL FRACTION | April 2021 | April 2025 | Allow | 48 | 3 | 0 | Yes | No |
| 17225991 | SYSTEMS AND METHODS FOR IDENTIFYING ASSOCIATIONS BETWEEN MICROBIAL STRAINS AND PHENOTYPIC FEATURES | April 2021 | November 2024 | Abandon | 43 | 2 | 0 | No | No |
| 17280804 | Method and Apparatus For Analysing a Sample | March 2021 | December 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17279900 | A NOISE MEASURE FOR COPY NUMBER ANALYSIS ON TARGETED PANEL SEQUENCING DATA | March 2021 | August 2025 | Allow | 52 | 2 | 1 | No | No |
| 17199391 | INCREMENTAL SECONDARY ANALYSIS OF NUCLEIC ACID SEQUENCES | March 2021 | May 2025 | Allow | 50 | 2 | 0 | Yes | No |
| 17196728 | METHOD AND SYSTEM FOR PROCESSING GENETIC DATA | March 2021 | January 2026 | Abandon | 58 | 6 | 0 | Yes | No |
| 17181865 | FAST-NA FOR THREAT DETECTION IN HIGH-THROUGHPUT SEQUENCING | February 2021 | November 2025 | Allow | 57 | 3 | 0 | Yes | No |
| 17158942 | Systems and Methods for Identifying and Expressing Gene Clusters | January 2021 | July 2025 | Allow | 53 | 6 | 0 | Yes | Yes |
| 17253833 | METHODS AND SYSTEMS FOR ASSESSING THE RISK OF GLAUCOMA | December 2020 | February 2025 | Allow | 49 | 2 | 0 | Yes | No |
| 16973687 | METHODS FOR OBJECTIVE ASSESSMENT OF STRESS, EARLY DETECTION OF RISK FOR STRESS DISORDERS, MATCHING INDIVIDUALS WITH TREATMENTS, MONITORING RESPONSE TO TREATMENT, AND NEW METHODS OF USE FOR DRUGS | December 2020 | September 2025 | Allow | 57 | 3 | 1 | No | No |
| 17114713 | METHOD AND APPARATUS FOR GENERATING NEW CHEMICAL STRUCTURE USING NEURAL NETWORK | December 2020 | December 2025 | Allow | 60 | 4 | 0 | Yes | No |
| 17098139 | SYSTEMS AND METHODS FOR DETERMINING STRUCTURAL VARIATION AND PHASING USING VARIANT CALL DATA | November 2020 | October 2025 | Abandon | 59 | 3 | 0 | Yes | No |
| 17051912 | METHODS AND TEST KITS FOR DETERMINING MALE FERTILITY STATUS | October 2020 | March 2025 | Abandon | 52 | 2 | 0 | No | No |
| 17075434 | Systems and Methods for Designing Vaccines | October 2020 | March 2025 | Allow | 53 | 4 | 0 | Yes | No |
| 17049075 | METHOD FOR PROVIDING TARGET NUCLEIC ACID SEQUENCE DATA SET OF TARGET NUCLEIC ACID MOLECULE | October 2020 | November 2025 | Allow | 60 | 3 | 0 | No | No |
| 17071774 | METHOD AND SYSTEM FOR POLYPROPYLENE AND POLYPROPYLENE ARTICLE PRODUCTION MODELING USING ARTIFICIAL INTELLIGENCE ALGORITHMS | October 2020 | July 2024 | Allow | 45 | 2 | 0 | Yes | No |
| 17068371 | SYSTEMS AND METHODS FOR ENGINEERING ENZYMES USING IDENTIFIED ENERGY TRANSFER NETWORKS | October 2020 | February 2025 | Allow | 52 | 2 | 0 | Yes | No |
| 17046371 | UP-SAMPLING OF SIGNALS BY ANALYTIC PHASE PROJECTION | October 2020 | May 2025 | Allow | 55 | 3 | 0 | Yes | No |
| 16980245 | METHOD FOR SCREENING COMPOUND FOR CONTROLLING RNA FUNCTION | September 2020 | July 2025 | Allow | 58 | 4 | 0 | Yes | No |
| 16978891 | HIGHLY MULTIPLEXED PHYLOGENETIC IMAGING OF MICROBIAL COMMUNITIES | September 2020 | May 2025 | Allow | 56 | 1 | 1 | Yes | No |
| 16976344 | VITAL INFORMATION DISPLAYING DEVICE, DISPLAY CONTROLLING DEVICE, AND NON-TRANSITORY COMPUTER-READABLE MEDIUM | August 2020 | November 2025 | Abandon | 60 | 4 | 0 | Yes | No |
| 16961120 | Processes for Genetic and Clinical Data Evaluation and Classification of Complex Human Traits | July 2020 | April 2025 | Allow | 57 | 4 | 0 | Yes | No |
| 16956585 | Method for Evaluation of Similarity between Dietary Fats to Human Milk Fat | June 2020 | November 2025 | Abandon | 60 | 4 | 0 | Yes | No |
| 16956243 | A METHOD OF DETERMINING THE EFFECT OF MOLECULAR SUPPLEMENTS ON THE GUT MICROBIOME | June 2020 | June 2025 | Abandon | 60 | 4 | 0 | Yes | No |
| 16883314 | STRUCTURE SEARCH APPARATUS, METHOD, AND RECORDING MEDIUM | May 2020 | February 2025 | Abandon | 57 | 3 | 0 | Yes | Yes |
| 16762619 | STRUCTURAL VARIANT ANALYSIS | May 2020 | May 2025 | Abandon | 60 | 3 | 0 | Yes | Yes |
| 16855239 | GENE ANALYSIS METHOD, GENE ANALYSIS APPARATUS, MANAGEMENT SERVER, GENE ANALYSIS SYSTEM, PROGRAM, AND STORAGE MEDIUM | April 2020 | March 2026 | Abandon | 60 | 5 | 0 | Yes | No |
| 16755926 | COPY NUMBER VARIATION DETECTION DEVICE AND METHOD | April 2020 | October 2025 | Abandon | 60 | 5 | 0 | No | No |
| 16647339 | DETECTING SOMATIC SINGLE NUCLEOTIDE VARIANTS FROM CELL-FREE NUCLEIC ACID WITH APPLICATION TO MINIMAL RESIDUAL DISEASE MONITORING | March 2020 | January 2026 | Allow | 60 | 2 | 1 | No | Yes |
| 16815366 | TECHNIQUES FOR DETERMINING ACID-BASE HOMEOSTASIS | March 2020 | December 2024 | Allow | 57 | 4 | 1 | Yes | No |
| 16638532 | Methods and systems for sequencing biomolecules for differential analysis of a test sample from a normal sample | February 2020 | December 2025 | Abandon | 60 | 5 | 0 | Yes | Yes |
| 16637975 | MATERIALS AND METHODS FOR STRATIFYING AND TREATING CANCERS | February 2020 | March 2025 | Allow | 60 | 5 | 1 | Yes | No |
| 16631976 | A DIAGNOSTIC AND PROGNOSTIC TEST FOR MULTIPLE CANCER TYPES BASED ON TRANSCRIPT PROFILING | January 2020 | November 2025 | Abandon | 60 | 4 | 0 | Yes | No |
| 16738669 | FISH FARM MATERIAL HANDLING | January 2020 | January 2025 | Abandon | 60 | 3 | 0 | No | No |
| 16626671 | METHODS FOR HIGH-RESOLUTION MICROBIOME ANALYSIS | December 2019 | November 2025 | Allow | 60 | 4 | 0 | Yes | No |
| 16701070 | PROTEIN STRUCTURE PREDICTION USING GEOMETRIC ATTENTION NEURAL NETWORKS | December 2019 | March 2025 | Allow | 60 | 3 | 0 | Yes | No |
| 16664265 | METHODS AND PROCESSES FOR NON-INVASIVE ANALYSIS OF CELL-FREE FETAL NUCLEIC ACID ACCORDING TO SEQUENCE READ QUANTIFICATIONS FOR CHROMOSOMES 13, 18, AND 21 | October 2019 | June 2025 | Allow | 60 | 4 | 0 | Yes | No |
| 16654349 | METHOD AND SYSTEM FOR COMPARING PROTEINS IN THREE DIMENSIONS | October 2019 | June 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16562183 | REVERSE CONCATENATION OF ERROR-CORRECTING CODES IN DNA DATA STORAGE | September 2019 | November 2024 | Allow | 60 | 4 | 0 | Yes | No |
| 16459052 | METHODS AND SYSTEMS FOR USING MACHINE-LEARNING MODELS TO ESTIMATE PEPTIDE-RETENTION TIME | July 2019 | May 2025 | Allow | 60 | 5 | 0 | Yes | No |
| 16368488 | METHOD FOR DESIGNING PRIMERS FOR MULTIPLEX PCR | March 2019 | December 2024 | Allow | 60 | 3 | 0 | No | No |
| 16191142 | SYSTEMS AND METHODS FOR DETERMINING MICROSATELLITE INSTABILITY | November 2018 | July 2024 | Allow | 60 | 4 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KALLAL, ROBERT JAMES.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KALLAL, ROBERT JAMES works in Art Unit 1685 and has examined 48 patent applications in our dataset. With an allowance rate of 62.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 58 months.
Examiner KALLAL, ROBERT JAMES's allowance rate of 62.5% places them in the 22% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KALLAL, ROBERT JAMES receive 3.15 office actions before reaching final disposition. This places the examiner in the 89% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by KALLAL, ROBERT JAMES is 58 months. This places the examiner in the 1% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +27.7% benefit to allowance rate for applications examined by KALLAL, ROBERT JAMES. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 24.0% of applications are subsequently allowed. This success rate is in the 34% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 16.7% of cases where such amendments are filed. This entry rate is in the 18% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 13.3% of allowed cases (in the 91% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.